Full-Time

National Account Director

Managed Markets

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$227k - $267.1kAnnually

Senior, Expert

Remote in USA

Category
Business Development
Business & Strategy
Required Skills
Sales
Requirements
  • Bachelor’s degree, MBA preferred
  • 10+ years of proven success in biotech/pharmaceutical industry (large account management experience is preferred)
  • Minimum of 5 years experience executing market access strategies for National PBM and Payer accounts, and exposure to contract development and negotiations
  • Endocrinology and Oncology experience preferred
  • Strong understanding of the US healthcare landscape, policy, and reimbursement
  • Ability to travel up to 50% of the time for customer engagements, and internal meetings
Responsibilities
  • In coordination with Market Access Leadership, develops a market access strategy aligned with Corcept’s commercial goals and ensures a comprehensive tactical plan is deployed to achieve commercial strategic objectives
  • Establish strong relationships with Pharmacy Directors, Medical Directors, and other strategic personnel within key assigned accounts
  • Deliver value proposition and Health Economic Information (HEI) to educate payers, formulary committees, and similar entities, on product(s) and economic benefit
  • Create, implement, and maintain detailed account plans for targeted accounts, including pre-launch, launch, and post-launch activities to maximize access and reimbursement
  • Ensure rapid and optimal access for all Corcept products
  • Provide appropriate insights and inputs into the development of payer PAs and, or Medical Policies
  • Assess sales implications of short- and long-term actions with each payer customer and take action to move payer decisions in a direction that continues to open patient access to care with Corcept products
  • Negotiate and measure contract performance (if applicable) with target accounts based on approved strategies
  • Collaborate with field teams (Sales, Medical, Patient Advocates, etc.) to identify any access barriers and partner with colleagues to mitigate
  • Work collaboratively with Specialty Pharmacy partners to ensure reimbursement confidence and unimpeded access in alignment with product FDA label
  • Provide periodic market updates to Commercial Leadership that link important provider, payer, and health care reform trends and issues as well as document initiatives and their outcomes
  • Ensures all activities are consistent with all US Healthcare regulations, laws, and company compliance policies

Corcept Therapeutics focuses on developing treatments that regulate cortisol, a hormone important for stress response, metabolism, and immune function. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. The company has discovered over 1,000 selective cortisol modulators and aims to expand its offerings with new treatments in development. Unlike many competitors, Corcept emphasizes both research and patient education, providing resources to improve understanding and care for cortisol-related conditions. The goal of Corcept is to advance the treatment of serious medical conditions linked to cortisol imbalance.

Company Stage

IPO

Total Funding

$42.6M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

23%

1 year growth

31%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.

Help us improve and share your feedback! Did you find this helpful?